ABSTRACT• Multidisciplinary discussion remains the cornerstone of ILD diagnosis and management, with recent advances furtherstrengthening the integration of clinical, radiological, pathological, and molecular information.• Updated ILD nomenclature and classification better align disease terminology with underlying morphology and pathobiology.• Growing emphasis is being placed on the early detection of ILD and on identifying individuals at high risk of progressionamong those with interstitial lung abnormalities (ILAs).• Emerging multi-omic biomarkers and quantitative imaging techniques are enhancing prognostic stratification and may sup-port future precision medicine approaches.• Novel antifibrotic therapies and targeted treatments are expanding therapeutic options beyond IPF, although importantunmet needs remain regarding patient selection, treatment response, and disease modification.• The integration of clinical, radiological, functional, and molecular information will be fundamental to optimize individual-ized management and improve long-term outcomes in patients with ILDs.
Magrì, T., Richeldi, L., Contemporary Concise Review 2025: Interstitial Lung Disease, <<RESPIROLOGY>>, 2026; 31 (10): 974-982. [doi:10.1002/resp.70309] [https://hdl.handle.net/10807/348136]
Contemporary Concise Review 2025: Interstitial Lung Disease
Richeldi, LucaUltimo
2026
Abstract
ABSTRACT• Multidisciplinary discussion remains the cornerstone of ILD diagnosis and management, with recent advances furtherstrengthening the integration of clinical, radiological, pathological, and molecular information.• Updated ILD nomenclature and classification better align disease terminology with underlying morphology and pathobiology.• Growing emphasis is being placed on the early detection of ILD and on identifying individuals at high risk of progressionamong those with interstitial lung abnormalities (ILAs).• Emerging multi-omic biomarkers and quantitative imaging techniques are enhancing prognostic stratification and may sup-port future precision medicine approaches.• Novel antifibrotic therapies and targeted treatments are expanding therapeutic options beyond IPF, although importantunmet needs remain regarding patient selection, treatment response, and disease modification.• The integration of clinical, radiological, functional, and molecular information will be fundamental to optimize individual-ized management and improve long-term outcomes in patients with ILDs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



